A. Tree

Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?

D. Dearnaley, V. Khoo, N. Van As, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?

V. Khoo, M. Partridge, N. Van As, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?

V. Khoo, D. Tait, H. Mandeville, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Journal Pre-proof Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: efficacy and toxicity in the DELINEATE trial

R. Gunapala, I. Blasiak-Wal, L. Truelove, 2019 .

Prostate stereotactic body radiotherapy—first UK experience.

V. Khoo, P. Hoskin, N. Van As, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

National survey of fiducial marker insertion for prostate image guided radiotherapy.

H. McNair, A. Tree, J. Kinsella, 2018, Radiography.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

R. Miralbell, F. Casamassima, B. Jereczek-Fossa, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.

K. Harrington, J. Murray, S. Gulliford, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Stereotactic body radiotherapy for prostate cancer.

N. Van As, A. Tree, D R Henderson, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).